Millennium Management’s AbCellera Biologics ABCL Stock Holding History

Millennium Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-250,000	Closed	-$1.15M	–	6007
2023 Q3	$1.15M	Buy	+250,000	New	+$1.52M	﹤0.01%	4081
2023 Q2	–	Sell	-300,000	Closed	-$2.26M	–	6041
2023 Q1	$2.26M	Buy	300,000 +139,100	+86%	+$1.26M	﹤0.01%	3320
2022 Q4	$1.63M	Sell	160,900 -139,100	-46%	-$1.61M	﹤0.01%	3731
2022 Q3	$2.97M	Buy	+300,000	New	+$3.29M	﹤0.01%	3401

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management's ABCL Position: Q1 2026 in Review

Millennium Management reduced its AbCellera Biologics (ABCL) stake by 27% in Q1 2026, selling an estimated $1.72M and leaving 1,294,574 shares worth $4.52M. The position accounts for ﹤0.01% of the portfolio, ranked #3067.

Millennium Management first reported a position in ABCL in Q4 2020 and has held it in 22 quarters since. The position peaked at $31.5M in Q2 2022. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

Millennium Management held 1,294,574 shares of AbCellera Biologics worth $4.52M as of Q1 2026.
Millennium Management sold 478,965 AbCellera Biologics shares in Q1 2026, an estimated $1.72M.
AbCellera Biologics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3067 holding.
Millennium Management first reported a position in AbCellera Biologics in Q4 2020 and has held it in 22 quarters since.
Millennium Management's AbCellera Biologics position peaked at $31.5M in Q2 2022.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.